ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
AEON Biopharma Inc

AEON Biopharma Inc (AEON)

0.1385
0.0105
( 8.20% )
Updated: 06:50:10

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
0.1385
Bid
-
Offer
-
Volume
14,836,157
0.13 Day's Range 0.1531
0.1013 52 Week Range 17.17
Market Cap
Previous Close
0.128
Open
0.1338
Last Trade
100
@
0.1385
Last Trade Time
06:49:49
Financial Volume
US$ 2,054,891
VWAP
0.138506
Average Volume (3m)
17,422,642
Shares Outstanding
39,970,693
Dividend Yield
-
PE Ratio
0.23
Earnings Per Share (EPS)
0.6
Revenue
52.75M
Net Profit
24.05M

About AEON Biopharma Inc

AEON Biopharma, Inc. is a bio-pharmaceutical company. The Company is focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets. ABP-450 contains a 900 kDa botulinum toxin type-... AEON Biopharma, Inc. is a bio-pharmaceutical company. The Company is focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets. ABP-450 contains a 900 kDa botulinum toxin type-A complex produced by the bacterium clostridium botulinum. The active part of the botulinum toxin is the 150 kDa component, and the remaining 750 kDa of the complex is made up of accessory proteins. When injected at therapeutic levels, ABP-450 blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the docking and release of acetylcholine from vesicles situated within the nerve endings leading to denervation and relaxation of the muscle. It is also engaged in the Phase II clinical study of ABP-450 for the treatment of cervical dystonia. Cervical dystonia, also known as spasmodic torticollis, is a neurological condition. Show more

Sector
Pharmaceutical Preparations
Industry
Blank Checks
Headquarters
Wilmington, Delaware, USA
Founded
2022
AEON Biopharma Inc is listed in the Pharmaceutical Preparations sector of the American Stock Exchange with ticker AEON. The last closing price for AEON Biopharma was US$0.13. Over the last year, AEON Biopharma shares have traded in a share price range of US$ 0.1013 to US$ 17.17.

AEON Biopharma currently has 39,970,693 shares in issue. The market capitalisation of AEON Biopharma is US$5.12 million. AEON Biopharma has a price to earnings ratio (PE ratio) of 0.23.

AEON Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0115-7.666666666670.150.16260.1189169600200.14278193CS
4-0.4715-77.29508196720.610.6290.1013582922610.17507846CS
12-0.7795-84.91285403050.9180.91990.1013174226420.17946295CS
26-2.3315-94.39271255062.472.99040.101376329380.19543993CS
52-8.3815-98.37441314558.5217.170.101342479380.45825601CS
156-10.0015-98.63412228810.1417.170.101328381270.50146841CS
260-10.0015-98.63412228810.1417.170.101328381270.50146841CS

AEON - Frequently Asked Questions (FAQ)

What is the current AEON Biopharma share price?
The current share price of AEON Biopharma is US$ 0.1385
How many AEON Biopharma shares are in issue?
AEON Biopharma has 39,970,693 shares in issue
What is the market cap of AEON Biopharma?
The market capitalisation of AEON Biopharma is USD 5.12M
What is the 1 year trading range for AEON Biopharma share price?
AEON Biopharma has traded in the range of US$ 0.1013 to US$ 17.17 during the past year
What is the PE ratio of AEON Biopharma?
The price to earnings ratio of AEON Biopharma is 0.23
What is the cash to sales ratio of AEON Biopharma?
The cash to sales ratio of AEON Biopharma is 0.11
What is the reporting currency for AEON Biopharma?
AEON Biopharma reports financial results in USD
What is the latest annual turnover for AEON Biopharma?
The latest annual turnover of AEON Biopharma is USD 52.75M
What is the latest annual profit for AEON Biopharma?
The latest annual profit of AEON Biopharma is USD 24.05M
What is the registered address of AEON Biopharma?
The registered address for AEON Biopharma is CORPORATION TRUST CENTER, 1209 ORANGE ST, NEW CASTLE, WILMINGTON, DELAWARE, 19801
Which industry sector does AEON Biopharma operate in?
AEON Biopharma operates in the BLANK CHECKS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DXFEason Technology Limited
 11.00
(12,343.44%)
1.96k
AXILAXIL Brands Inc
US$ 6.64
(39.85%)
63.85k
EXODExodus Movement Inc
US$ 55.80
(26.82%)
144.72k
NVOXDefiance Daily Target 2x Long Nvo ETF
US$ 11.91
(16.31%)
191.67k
AMBOAmbow Education Holding Ltd
US$ 2.17
(14.21%)
36.5k
TPETTrio Petroleum Corp
US$ 1.56
(-22.39%)
1.99M
TOPPToppoint Holdings Inc
US$ 3.039
(-17.72%)
95.4k
CHROChannel Therapeutics Corporation
US$ 2.4351
(-12.72%)
215.98k
ETQT Rex 2X Inverse Ether Daily Target ETF
US$ 8.66
(-9.03%)
6.6k
ETHDProshares Ultrashort Ether ETF
US$ 20.145
(-8.68%)
174.07k
BTGB2Gold Corp
US$ 2.395
(1.91%)
64.66M
NVDQT Rex 2X Inverse NVIDIA Daily Target ETF
US$ 2.832
(6.07%)
50.44M
SOXLDirexion Daily Semiconductor Bull 3X Shares
US$ 32.555
(-6.77%)
45.24M
SPXSDirexion Daily S&P 500 Bear 3X Shares New
US$ 5.66
(1.07%)
35.34M
DNNDenison Mines Corp
US$ 2.025
(-0.98%)
34.55M

AEON Discussion

View Posts
tw0122 tw0122 1 week ago
All out at .19 good luck nice bottoming 
👍️0
glenn1919 glenn1919 1 week ago
AEON.......................................@.20 .........................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783







............thx.......................
👍️0
tw0122 tw0122 1 week ago
Bounce bounce break .14 see .20
At .13
👍️0
Backstabbed Backstabbed 2 weeks ago
$AEON - 2 filings released AH! SC-13G
👍️0
0210 0210 3 weeks ago
93m shs traded = 50m buys + 8m(?) vs. 35m sells: https://ih.advfn.com/stock-market/AMEX/aeon-biopharma-AEON/trades
👍️0
0210 0210 3 weeks ago
new lows still, hah! hmmm.....interesting AEON teens & twenties.
👍️0
0210 0210 3 weeks ago
aeon aeON AEON https://www.benzinga.com/news/25/01/42821213/why-aeon-biopharma-stock-is-down-65-today
👍️0
0210 0210 3 weeks ago
A/S 500m O/S 40m Float 10m. 70m traded so far today. buys > sells. hmmm....
👍️0
0210 0210 3 weeks ago
AEON 19-20cents way below all-time VWAPs and 50cents $20m new offering price!? hmmm....chap 11 pps? lolol.
👍️0
ErnieBilco ErnieBilco 3 weeks ago
Offering meltdown TIME TO BUY
👍️0
glenn1919 glenn1919 4 months ago
AEON............................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 5 months ago
AEON new 52=week low
👍️0
willlbone willlbone 6 months ago
Dilution.
👍️0
glenn1919 glenn1919 6 months ago
AEON.......................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 6 months ago
AEON under $3
👍️0
glenn1919 glenn1919 6 months ago
AEON..............................................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783
👍️0
DewDiligence DewDiligence 7 months ago
AEON repositions ABP-450 as_a potential Botox biosimilar:

https://finance.yahoo.com/news/aeon-biopharma-announces-strategic-reprioritization-120000126.html

AEON is nearly insolvent (#msg-174417740), so it’s hard to see how they complete a phase-3 trial to obtain FDA approval using the 351(k) pathway.

This looks like another instance of Zebra’s Law.

Reminder: ABP-450 is the same drug as EOLS’ Jeuveau, sourced from Korea’s Daewoong.
👍️0
Monksdream Monksdream 7 months ago
AEON new 52 week low
👍️0
Monksdream Monksdream 7 months ago
AEON new 52 week low
👍️0
DewDiligence DewDiligence 8 months ago
AEON—>55% workforce reduction—ABP-450 clinical development suspended:

https://finance.yahoo.com/news/aeon-biopharma-announces-strategic-reprioritization-120000294.html Upon securing additional capital, we would be positioned to announce a revised clinical development strategy for our pipeline of ABP-450 programs. AEON is all but insolvent—see #msg-174417740.

Reminder: ABP-450 is the same drug as EOLS’ Jeuveau, sourced from Korea’s Daewoong.
👍️0
DewDiligence DewDiligence 8 months ago
AEON has a liquidity problem—1Q24 results:

https://www.globenewswire.com/news-release/2024/05/14/2881873/0/en/AEON-Biopharma-Reports-First-Quarter-2024-Financial-Results.html

Net current assets at 3/31/24 were negative ($13.5M). Hence, even after accounting for the $15.0M AEON received from its supplier, Daewoong in an Apr 2024 private placement, net current assets as of today are either close to zero or negative.

No CC.
👍️0
DewDiligence DewDiligence 9 months ago
AEON plows on despite setbacks:

https://www.globenewswire.com/news-release/2024/05/09/2878729/0/en/AEON-Biopharma-Provides-Update-on-Development-Pipeline.html
👍️0
Monksdream Monksdream 9 months ago
AEON new 52+ week low
👍️0
DewDiligence DewDiligence 9 months ago
AEON—(-53%)—reports failed phase-2 in migraine prevention:

https://finance.yahoo.com/news/aeon-biopharma-announces-preliminary-top-110000987.html AEON Biopharma…today announced that the preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventive treatment for chronic migraine did not meet the primary endpoint. This is AEON’s second phase-2 failure in migraine, having whiffed in a prior phase-2 for treatment (rather than prevention) of episodic migraine (#msg-173058579).

AEON’s ABP-450 is the exact same drug as EOLS’ Jeuveau, sourced from Korea's Daewoong.

AEON’s lead indication had previously been cervical dystonia, but AEON backed off from CD after RVNC reported stellar data in that indication.

Please see #msg-172274907 for related info.
👍️0
DewDiligence DewDiligence 10 months ago
Dilution from the redemption of warrants:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001837607/000183760724000017/aeon-20240329x8k.htm
👍️0
trglaa trglaa 10 months ago
What happened here today?
👍️0
DewDiligence DewDiligence 10 months ago
AEON 4Q23 financials:

https://www.globenewswire.com/news-release/2024/03/29/2854830/0/en/AEON-Biopharma-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
👍️0
DewDiligence DewDiligence 10 months ago
AEON updates plans for migraine program:

https://finance.yahoo.com/news/aeon-biopharma-announces-clinical-productive-203000664.html
👍️0
DewDiligence DewDiligence 10 months ago
AEON sells $15M of convertible debt to_supplier, Daewoong:

https://finance.yahoo.com/news/aeon-biopharma-announces-15-million-202900910.html
👍️0
DewDiligence DewDiligence 1 year ago
AEON presents phase-2 data in cervical dystonia:

https://finance.yahoo.com/news/aeon-biopharma-presents-positive-clinical-210500488.html

CD had been AEON’s lead indication for ABP-450, but AEON changed gears and made episodic migraine the lead indication after RVNC reported Daxxify data in CD (https://www.sec.gov/Archives/edgar/data/1837607/000110465923063774/tm2316532d1_ex99-1.htm ). When AEON’s phase-2 in episodic migraine failed in Oct 2023 (#msg-173058579), CD again became the lead indication by default.

The above PR also includes preclinical data for ABP-450 in PTSD (!?).

AEON needs to raise a significant amount of cash to conduct a phase-3 trial in any indication (#msg-173211412).

Reminder: ABP-450, sourced from Korea’s Daewoong, is the exact same toxin as EOLS’ Jeuveau. See #msg-172274907 for background info.
👍️0
DewDiligence DewDiligence 1 year ago
AEON needs to raise cash very soon:

https://www.globenewswire.com/news-release/2023/11/13/2779046/0/en/AEON-Biopharma-Reports-Third-Quarter-2023-Financial-Results.html The Company reported cash, cash equivalents and investments were approximately $16.2 million as of September 30, 2023.

The Company believes its cash, cash equivalents and investments will be sufficient to fund its planned clinical studies, as well as support corporate operations into mid-December 2023. No quarterly CC.
👍️0
DewDiligence DewDiligence 1 year ago
AEON phase-2 trial_in episodic migraine misses_ primary_endpoint:

https://finance.yahoo.com/news/aeon-biopharma-announces-topline-results-200500504.html On the primary endpoint, the topline data showed ABP-450 had a treatment effect with mean reductions in MMD [monthly migraine days] of 4.8 days at the 150U dose (n = 99) and 5.0 days at the 195U dose (n = 108), compared to only 4.2 days in placebo (n = 98) at weeks 21-24, but did not meet statistical significance… Episodic migraine is (was) ABP-450’s lead indication. The lead indication had previously been cervical dystonia, but AEON backed off from CD due, presumably, to RVNC’s stellar dataset in that indication.

AEON’s ABP-450 is the exact same drug as EOLS’ Jeuveau. Please see #msg-172274907 for related info.
👍️0
DewDiligence DewDiligence 1 year ago
AEON's trading liquidity is so low it doesn't take much to move the share price. Today's news was actually minor in the overall scheme of things insofar as AEON has apparently put the brakes on its clinical program in cervical dystonia in order to pursue episodic migraine.
👍️0
trglaa trglaa 1 year ago
Nice run today.
👍️0
DewDiligence DewDiligence 1 year ago
AEON presents phase-2 data in cervical dystonia:

https://finance.yahoo.com/news/aeon-biopharma-presents-positive-results-120000687.html

Note: Episodic migraine, rather than cervical dystonia, is now AEON’s lead indication for ABP-450. This change is presumably due to RVNC’s robust data in cervical dystonia and the recent FDA approval of Daxxify for CD.

See #msg-172274963 for related info.
👍️0
DewDiligence DewDiligence 2 years ago
AEON's initial press release:

https://finance.yahoo.com/news/aeon-biopharma-announces-closing-business-110000037.html
👍️0
TESLA777 TESLA777 2 years ago
$AEON This is the one Im watching/trading tomorrow....GLTY......
👍️0
DewDiligence DewDiligence 2 years ago
AEON’s corporate slide presentation:

https://www.sec.gov/Archives/edgar/data/1837607/000110465923063774/tm2316532d1_ex99-1.htm

Notably, AEON’s lead indication is now episodic migraine. AEON’s lead indication was previously cervical dystonia, so it seems reasonable to surmise that RVNC’s stellar data in CD altered AEON’s plans.
👍️0
DewDiligence DewDiligence 2 years ago
AEON seeks_to_compete_in_the therapeutic—(rather than aesthetic)—market_for botulinum toxin. AEON's botulinum toxin, ABP-450 is the exact same product as EOLS’ Jeuveau, sourced from Korea's Daewoong.
👍️0
DewDiligence DewDiligence 2 years ago
AEON Biopharma begins_trading_7/24/23_under_the_symbol, AEON, following the closing of the SPAC merger with PMGM:

https://finance.yahoo.com/news/priveterra-acquisition-corp-announces-completion-202700149.html
👍️0

Your Recent History

Delayed Upgrade Clock